Core R&D Programs

The Radiation Protection Platform – Our Scientific Bedrock

Research and development of protective solutions against the harmful effects of electromagnetic and nuclear radiation.
Serves as the scientific core for our interventions in fatigue and applications in healthy aging.
A forward-looking investment in a domain critical to national biosecurity.

Lead Oncology Immunotherapy
Asset – Anti-GDF15 Neutralizing Monoclonal Antibody

Status: China Class 1 Innovative Drug.
Initial Indication:  Targeting immune evasion in hepatocellular carcinoma (Liver Cancer).
Significance: Designated as a key innovative drug project by the National Health Commission (NHC). This designation underscores the urgent unmet medical need, as liver cancer currently lacks truly effective pharmaceutical interventions.
Platform Potential:
While our initial focus is on liver cancer, the GDF-15 pathway is implicated in the immune evasion of multiple tumor types. This positions our antibody as a potential foundational therapy for a broad spectrum of cancers, creating significant long-term value.
Approach: A globally synchronized R&D program in this cutting-edge field.
In December 2025, the technology transfer agreement was executed to accelerate project industrialization.
Listed on the Shanghai Technology Exchange (Listing No.: Z202250159).

Radiation-Resistant Anti-Aging and Anti-Fatigue Health Products

Evidence-based formulations derived from our foundational radiation protection research.
Designed to enhance physical performance, promote cellular repair mechanisms, and mitigate fatigue.
Applicable to a wide demographic, including military personnel, elite athletes, and the general population seeking enhanced vitality.
An expanding focus on technologies for healthy aging and longevity.

Leveraging the strategic advantages of Hong Kong's "International Chinese Medicine Hub", we integrate top-tier international and domestic scientific expertise to ensure our R&D output meets and exceeds the highest global standards.